EcoDrugPlus

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSSLUG00000012958
Gene Symbol: PSMB3
3 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSSLUG00000017077
Gene Symbol: PSMB4
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSSLUG00000005195
Gene Symbol: PSMB5
1 Cross references
203 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSSLUG00000016587
Gene Symbol: PSMB6
1 Cross references
230 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSSLUG00000021089
Gene Symbol: PSMB7
3 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSSLUG00000003790
Gene Symbol: PSMB8
3 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSSLUG00000003702
Gene Symbol: PSMB9A
1 Cross references
177 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSSLUG00000003283
Gene Symbol: PSMB9A
1 Cross references
183 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSSLUG00000013139
Gene Symbol: PSMD4A
1 Cross references
226 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSSLUG00000012752
Gene Symbol: PSMC1
3 Cross references
281 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSSLUG00000009275
Gene Symbol: PSMC2
3 Cross references
232 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSSLUG00000006295
Gene Symbol: PSMC3
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).